Alejandro Moles‐Fernández

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara et al. · EMBO Molecular Medicine · 2018 · 274 citations · Full text

Medicine, Cancer Biology, Oncology +9

Large scale multifactorial likelihood quantitative analysis of <i>BRCA1</i> and <i>BRCA2</i> variants: An ENIGMA resource to support clinical variant classification

Michael T. Parsons, Emma Tudini, Hongyan Li et al. · Human Mutation · 2019 · 152 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Preclinical <i>In Vivo</i> Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Benedetta Pellegrino, Andrea Herencia-Ropero, Alba Llop‐Guevara et al. · Cancer Research · 2022 · 97 citations · Full text

Medicine, Genetics, Oncology +15

Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings

Sandra Bonache, I. Esteban, Alejandro Moles‐Fernández et al. · Journal of Cancer Research and Clinical Oncology · 2018 · 65 citations · Full text

Medicine, Genetics, Oncology +13

Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?

Alejandro Moles‐Fernández, Laura Duran-Lozano, Gemma Montalban et al. · Frontiers in Genetics · 2018 · 64 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +17